Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia

Anna Pawłowska(City of Hope), Bruce Bostrom(Minnesota West Community & Technical College), D Baronciani(Centro di Riferimento Oncologico), Emanuele Angelucci(Ospedale Policlinico San Martino), BR Blazar(University of Minnesota Medical Center), X-O Shu(University of Minnesota)

Bone Marrow Transplantation

December 1, 1997

10.1038/sj.bmt.1701001

Cited by 58

Related Papers

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

|The Lancet Haematology|2020|553

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

|Blood|2002|496

Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel

|Haematologica|2014|389

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

|Blood|2003|361

Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia

|New England Journal of Medicine|1987|334